Welcome to our dedicated page for Simulations Plus SEC filings (Ticker: SLP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
For investors following the niche world of pharmaceutical modeling software, Simulations Plus disclosures are a goldmine—yet finding R&D spending trends or segment revenue inside a dense filing can be daunting. Whether you’re searching for “Simulations Plus quarterly earnings report 10-Q filing” before an update, or need “Simulations Plus proxy statement executive compensation” details to benchmark management incentives, our page brings every document to your screen in seconds.
Stock Titan’s platform pairs real-time EDGAR feeds with AI-powered summaries, so “Simulations Plus SEC filings explained simply” is more than a promise. Our algorithms surface key metrics—software license growth, consulting backlog, new ADMET model releases—and flag “Simulations Plus 8-K material events explained” the moment they post. You can review “Simulations Plus insider trading Form 4 transactions” or set alerts for “Simulations Plus Form 4 insider transactions real-time” to monitor when executives buy or sell shares. Need deeper context? Click once and you’re “understanding Simulations Plus SEC documents with AI” as complicated accounting notes are distilled into plain language.
- “Simulations Plus annual report 10-K simplified” highlights long-term revenue drivers and R&D capitalization choices.
- “Simulations Plus earnings report filing analysis” breaks down quarter-over-quarter operating margin movements.
- “Simulations Plus executive stock transactions Form 4” lists every option exercise alongside historical price graphs.
From the initial S-1 to the latest 10-K, every filing type is archived, searchable, and enriched with expert commentary. Save hours locating segment data, assess insider sentiment before material announcements, and compare performance across years—all in one place.
Simulations Plus (SLP), a provider of cheminformatics and biosimulation solutions for the biopharma industry, announced a rescheduling of its Q3 FY2025 financial results release and conference call. The company has delayed these events from the original date of July 2, 2025, to the following schedule:
- Conference call: July 14, 2025, at 5:00 p.m. Eastern Time
- Financial results release: July 15, 2025, before market open
The delay utilizes the maximum time allowed under regulations following the company's status change from a large accelerated filer to a non-accelerated filer. This material event was reported via Form 8-K and includes a press release (Exhibit 99.1) containing the rescheduling details. The filing indicates a notable change in the company's filing status and timing of financial disclosures, which could be significant for investors tracking reporting obligations and corporate governance.
FAQ
What is the current stock price of Simulations Plus (SLP)?
What is the market cap of Simulations Plus (SLP)?
What is the primary focus of Simulations Plus Inc?
Which operating segments does the company have?
How does Simulations Plus Inc support pharmaceutical research?
What type of technologies does the company utilize?
How is the company positioned in the global market?
What sets Simulations Plus Inc apart from its competitors?
